Skip to content

ABLD · Euronext Paris · ISIN FR001400AHX6

ABL Texcell Diagnostics, Advanced Biological Laboratories
UltraGene®CE-IVD

UltraGene® Assay SARS-CoV-2 Universalis

SARS-CoV-2 RNA detection · 50 or 1000 tests

SARS-CoV-2

UltraGene® Assay SARS-CoV-2 Universalis

Overview

The UltraGene Assay SARS-CoV-2 Universalis (V2.X) is a real-time RT-PCR test intended for the qualitative detection of RNA from the SARS-CoV-2 in upper respiratory specimens from individuals suspected of COVID-19 by their healthcare provider

Specifications

Specimens

  • Upper respiratory specimens (nasal, mid-turbinate, nasopharyngeal, oropharyngeal swab specimens and nasopharyngeal wash/aspirate or nasal aspirate and bronchoalveolar lavage (BAL) fluid specimens) from individuals suspected of COVID-19 by their healthcare provider

Formats

  • 50 or 1000 tests per kit
  • Multiplex format in 1 well per sample

Kit contents

  • Master Mix 2X, RT Mix, Enzyme Mix and Magnesium Sulfate
  • Specific Primers & Probes for each targeted gene: N, ORF1ab (RdRp)
  • Positive control
  • Negative control
  • Internal control
  • PCR grade nuclease-free water

Extraction

  • Magnetic beads
  • Validated for use with:
  • Seegene STARlet instrument (Cat. #67930-03) with Hamilton Run Control software (version 4.5.0.7977)
  • Seegene STARMag 96 X 4 Universal Cartridge Kit (Cat. #744300.4.UC384)
  • Any laboratory validated instrument for RNA extraction and purification using magnetic-bead technology shall work

Compatible instruments

  • Any qPCR instrument compatible with the FAM, HEX, ROX and Cy5 channels.
  • Validated for use with:
  • C1000 Dx Thermal Cycler (Bio-Rad, Catalog # 1841000-IVD with CFX96-Dx ORM software version 3.1) (C1000 CFX96),
  • QuantStudio 5 Real-Time PCR Instrument (96-Well 0.1mL Block) (Applied Biosystems, Catalog #A28133, Design & Analysis Software 1.5.2 / Firmware Version 1.4.0)

Workflow

  • Less than 20 minutes for up to 48 samples
  • Less than 40 minutes for up to 96 samples

Performance

Limit of detection (LOD)
1.15 TCID50/mL for SARS-CoV-2 with the C1000 CFX96 Dx Thermal Cycler and the QuantStudio 5 Real-Time PCR Instruments
Clinical performance evaluation
The positive (PPA) and negative (NPA) percent agreements between the UltraGene Assay SARS-CoV-2 Universalis V2.X and CE-IVD EUA test are for the C1000 CFX96: PPA = 28/28 = 100% (95% C.I. = 84.98% – 100%) NPA = 30/30 = 100% (95% C.I. = 85.86% – 100%)
Clinical Accuracy
Clinical Accuracy at 96%